Skip to main content
Back to Bessemer Venture Partners

Bessemer Venture Partners's Biotechnology Portfolio

Browse 14 Biotechnology companies funded by Bessemer Venture Partners. See funding amounts, founder contacts, and investment details.

Biotechnology Companies
14
Total Funding in Biotechnology
$1.3B

Biotechnology Portfolio Companies (14)

Export
BiotechnologyHealth CareMedical DeviceTherapeutics

Fractyl Health is a biotechnology company that provides curative therapies for metabolic diseases.

Lexington, United States
September 2025
$60.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareLife ScienceMedical

Seismic Therapeutic is a biotechnology company developing machine-learning technology for immunology drug development.

Watertown, United States
September 2024
$25.0M
Series B

Founder Contacts

30,000+ verified contacts

BiotechnologyPharmaceutical

We are a translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered proteins.

London, United Kingdom
June 2022
$40.0M
Series A

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CarePharmaceutical

Florence is a clinical trials platform that connects pharmaceutical companies and study sites to decentralize trials for drug development.

Atlanta, United States
June 2022
$27.0M
Series C

Founder Contacts

30,000+ verified contacts

BiotechnologyMedical

Inductive Bio provides the information, machine learning, tools, and know-how required to resolve ADMET issues.

San Francisco, United States
May 2025
$25.0M
Series A

Founder Contacts

30,000+ verified contacts

BiotechnologyPharmaceuticalTherapeutics

Allena Pharmaceuticals develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.

Newton, United States
May 2022
$2.8M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareNeurosciencePersonal HealthPrecision Medicine

Nido Biosciences is a clinical-stage company that develops precision medicines for severe neurological diseases.

Watertown, United States
May 2023
$86.6M
Series B

Founder Contacts

30,000+ verified contacts

BiotechnologyInformation TechnologyLife Science

Watershed Informatics catalyzes discovery by democratizing access to bioinformatics tools for biologists.

Cambridge, United States
March 2023
$14.5M
Series A

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyPharmaceuticalTherapeutics

Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease.

Lexington, United States
December 2025
$120.0M
Series B

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CarePharmaceuticalTherapeutics

TScan Therapeutics is a biopharmaceutical company focused on the development of immunotherapy treatments for cancer.

Waltham, United States
December 2024
$30.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareMedicalTherapeutics

Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.

Cambridge, United States
December 2025
$602.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

Artificial Intelligence (AI)BiotechnologyMedical

Converge Bio integrates Generative AI with biological data.

Wilmington, United States
January 2026
$25.0M
Series A

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyMedicalPharmaceutical

Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.

Watertown, United States
January 2025
$200.0M
Series A

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyPharmaceutical

Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.

Needham, United States
November 2025
$90.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

Explore Bessemer Venture Partners's Full Portfolio

View all companies funded by Bessemer Venture Partners across every industry and funding stage.

View Full Bessemer Venture Partners Portfolio